08:28 AM EDT, 09/22/2025 (MT Newswires) -- Coya Therapeutics ( COYA ) said Monday it has launched a phase 2 trial, called ALSTARTS, to research the efficacy and safety of its COYA 302 therapy candidate to treat amyotrophic lateral sclerosis, commonly known as ALS.

The company said that the ALSTARS study will be a randomized, placebo-controlled study with 120 participants at about 25 centers in the United States and Canada.

Coya said eligible participants will receive either one of two doses of COYA 302 or the placebo in a 24-week, double-blind study.

Participants who complete the initial phase will be invited to enroll in an additional 24-week extension to assess the long-term safety and efficacy of COYA 302, the company added.